Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation
$PRCT
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2023 | $42.00 | Overweight | Piper Sandler |
| 5/31/2023 | Outperform | William Blair | |
| 10/31/2022 | Neutral | BTIG Research | |
| 10/25/2022 | $58.00 | Buy | Truist |
| 9/2/2022 | $49.00 | Overweight | Wells Fargo |
| 7/15/2022 | $47.00 | Overweight | KeyBanc Capital Markets |
| 6/23/2022 | $53.00 | Buy | B. Riley Securities |
| 3/9/2022 | $48.00 → $42.00 | Buy | B of A Securities |
4 analysts have expressed a variety of opinions on PROCEPT BioRobotics (NASDAQ:PRCT) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for PROCEPT BioRobotics, presenting an average target of $75.25, a high estimate of $79.00, and a low estimate of $72.00. Surpassing
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and raises the price target from $72 to $79.
PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association ("AMA") has established a new Current Procedural Terminology ("CPT") Category I code for transurethral waterjet resection of prostate tissue ("Aquablation therapy") to treat benign prostatic hyperplasia ("BPH"). In response to increased utilization of Aquablation therapy and strong evidence for its clinical outcomes, the AMA accepted PROCEPT BioRobotics' application for a Category I CPT code, which will replace the existing Category III CPT code starting January 1,
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) ("PROCEPT BioRobotics" or the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company's common stock at the public offering price
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) ("PROCEPT BioRobotics" or the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company's common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions,
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $58.4 million for the third quarter of 2024, an increase of 66% compared to the prior period in 2023U.S. handpiece and consumables revenue of $29.6 million for the third quarter of 2024, an increase of 74% compared to the prior period in 2023Sold 45 robotic systems in the U.S. in the third quarter of 2024
SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/yhamkcsz Dial-in registration for sell-side re
SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. "We are pleased to bring the H
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13D/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13D/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
424B5 - PROCEPT BioRobotics Corp (0001588978) (Filer)
424B5 - PROCEPT BioRobotics Corp (0001588978) (Filer)
Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00
William Blair initiated coverage of PROCEPT BioRobotics with a rating of Outperform
BTIG Research initiated coverage of PROCEPT BioRobotics with a rating of Neutral